

Note

Rearrangement of 4-Amino-3-halo-pyridines by Nucleophilic Aromatic Substitution

Matthäus Getlik, Brian J. Wilson, M. Monzur Morshed, Iain D. G.
Watson, Doris Tang, Pandiaraju Subramanian, and Rima Al-awar

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jo4003773 • Publication Date (Web): 09 May 2013

Downloaded from <http://pubs.acs.org> on May 11, 2013

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications
High quality. High impact.

The Journal of Organic Chemistry is published by the American Chemical Society.
1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.


Rearrangement of 4-Amino-3-halo-pyridines by Nucleophilic Aromatic Substitution

Matthäus Getlik,[†] Brian J. Wilson,[†] M. Monzur Morshed,[†] Iain D. G. Watson,[†] Doris Tang,[†]
Pandiaraju Subramanian,[†] Rima Al-awar^{†,‡,*}

[†]*Drug Discovery Program, Ontario Institute for Cancer Research, 101 College Street, MaRS
Centre, South Tower, Toronto, Ontario, M5G 0A3, Canada.* [‡]*Department of Pharmacology and
Toxicology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto
ON M5S 1A8*

*Rima.Alawar@oicr.on.ca

ABSTRACT




The reaction of 3-halo-4-aminopyridines with acyl chlorides and triethylamine is described. The pyridin-4-yl α -substituted acetamide products were obtained in moderate to high yields. The presented rearrangement reaction, in which the presumed *N*-acylated intermediate reacts intramolecularly via nucleophilic aromatic substitution, results in a formal two carbon insertion.

Rearrangements are especially elegant reactions, leading to non-obvious products via intramolecular bond breakage and formation.^{1,2} Through atom or atom group migration they can provide access to complex molecules and are valuable transformations in natural product synthesis, heterocyclic chemistry, and industrial processes.³⁻⁸ The Smiles rearrangement is an intramolecular nucleophilic substitution in which an aromatic system shifts from one heteroatom to another via a spirocyclic intermediate. Usually, the nucleophilic heteroatom of phenols or anilines intramolecularly attacks a second aromatic ring, which is activated by electron withdrawing substituents ortho or para to the attacked position.⁹⁻¹³

In the Smiles-Truce rearrangement, an extended variant of the Smiles rearrangement, the nucleophilic attack is carried out by a carbanion and leads to the formation of a new C-C bond making it an attractive reaction for synthetic chemists (Scheme 1).^{2, 12, 14, 15}

SCHEME 1. C-C bond forming rearrangements (1) Smiles-Truce rearrangement (2) *N*-acyl aminopyridine rearrangement.



In this study, we wish to report the facile synthesis of pyridin-4-yl α -substituted acetamides. The rearrangement of *in situ* generated intermediate **B** leads to the insertion of a two carbon unit into the C-N bond of 4-aminopyridine **A**. We suggest that intramolecular nucleophilic attack by the enol (**B**) leads to the breakage of a C-N bond and the formation of a new C-C bond (Scheme 1). The obtained pyridin-4-yl α -substituted acetamide products (**C**) constitute synthetically useful products for the synthesis of functionalized molecules.^{16,17} The herein described pyridin-4-yl α -substituted acetamides are synthetically demanding synthons and to our best knowledge have not been reported previously in the literature.

In the original attempt to *N*-acylate **1a**, adding triethylamine (7 equiv) and chloro acetyl chloride (7 equiv) in THF at room temperature, the starting material **1a** was consumed overnight and 2-chloro-2-(3-chloropyridin-4-yl)-*N*-(2,4-dimethoxybenzyl) acetamide **2a** was isolated in 79% yield (Table 1, entry 1). However, the isolated product proved not to be the anticipated *N*-acylated compound. Single-crystal X-ray analysis confirmed the formation of the unexpected rearrangement product **2a** (Figure 1).





FIGURE 1. Crystal structure of **2a**.

Motivated by the potential scope and applicability of this reaction, we decided to further investigate our initial findings. Examination of the reaction conditions found that excess and/or repeated addition of reactants was crucial for complete turnover of the starting material (not achieved for every substrate). We propose that triethylamine promotes dehydrohalogenation of chloro acetyl chloride to generate a ketene *in situ* - ketenes are known to form under the given conditions - which subsequently reacts with **1a**.¹⁸ As reported by Sauer and others,¹⁹⁻²¹ the high reactivity of ketenes often leads to dimerization and polymerization byproducts, and could explain the requirement for an excess of reagents. For strongly exothermic reactions, lowering the temperature to 0 °C increased the isolated yields. Overall, the reaction appeared to be cleaner in THF than in CH₂Cl₂ or toluene and thus became the solvent of choice for further studies.

We subjected various substituted 4-aminopyridines to the optimized conditions and found that halogen (**1a-d**) and methyl (**1e**) substituents in the 3-position were tolerated, whereas introduction of a nitrile (**1f**) or methyl acetate group (**1g**) led to *N*-acylation or no reaction (Table 1). Interestingly, subjecting *N*-(2,4-dimethoxybenzyl)-3-fluoropyridin-4-amine (**1b**) to the standard reaction conditions resulted in a mixture of the rearranged and the *N*-acylated products **2b** and **3a** in a 2.5:1 ratio. However, the same substrate (**1b**) gave solely the rearranged product *N*-(2,4-dimethoxybenzyl)-2-(3-fluoropyridin-4-yl)-2-phenoxyacetamide (**2r**) when treated with phenoxyacetyl chloride.

TABLE 1. Rearrangement of 3-substituted 4-amino-pyridines

entry	subst.	R	product		yield [%]
			rearranged	N-acylated	
1	1a	3-Cl	2a	-	79
2	1b	3-F	2b	3a	12/3
3	1c	3-Br	2c	-	84
4	1d	3-I	2d	-	29
5	1e	3-Me	2e	-	10
6	1f	3-CN	-	3b	14
7	1g	3-CO ₂ Me	-	-	-
8	1h	2-Cl	-	3c	47
9	1i	2-CN	-	3d	98

Electron withdrawing halides in the 3-position seem to enable the nucleophilic attack at the pyridine's ipso-carbon (C-4). A comparable activation of an aromatic substrate is observed in the Smiles rearrangement, where ortho- or para-activating substituents are required in the migrating aryl moiety.^{1,2} Despite the electron withdrawing character of nitrile and methyl ester substituents, decoration of the pyridine with these moieties did not allow substrates **1f** and **1g** to rearrange. Surprisingly, methyl-substitution in the 3-position yielded the rearranged product.

The para-position of the ring nitrogen with respect to the reactive centre proved to be essential for the reaction, since moving the heteroatom to another position in the ring did not allow the substrates 5-bromo-2-chloro-*N*-(2,4-dimethoxybenzyl)pyridin-3-amine and 3-chloro-*N*-(2,4-dimethoxybenzyl)pyridin-2-amine to undergo rearrangement. In addition to the importance of the substituents in the 3-position, the pyridine nitrogen further withdraws electron density from the aromatic ring and thus increases the electrophilicity of the reacting ipso-carbon.


Substitution in the 2-position (**1h** and **1i**) led to *N*-acylated products (**3c-d**). No substitution of the pyridine ring (*N*-(2,4-dimethoxybenzyl)pyridin-4-amine) gave an unstable product that could not be isolated. Multiple substituents on the pyridine core were not tolerated as substrates for this reaction (methyl 3-chloro-4-((2,4-dimethoxybenzyl)amino)picolinate and (3-chloro-4-((2,4-dimethoxybenzyl)amino)pyridin-2-yl)methanol). We then turned our attention to the amino-substituent and explored its influence on the rearrangement reaction (Table 2). Although this position appeared to accept a wide range of substituents from benzylic (**1a**, **1j-n**), and aromatic (**1o**) to aliphatic (**1p-q**) residues (Table 2), the 2,4-dimethoxybenzyl group afforded the best yield.

TABLE 2. Influence of the nitrogen-substituent on the rearrangement

entry	subst.	R	product	yield [%]
1	1a		2a	79
2	1j		2f	63
3	1k		2g	69
4	1l		2h	34
5	1m		2i	53
6	1n		2j	54
7	1o		2k	53
8	1p		2l	35
9	1q		2m	32

To further illustrate the synthetic value of this method, we investigated the applicability of various acyl chlorides. A focused set was employed for the generation of mono- or disubstituted ketenes which all afforded the rearranged product in excellent yields ranging from 79 to 97% (Table 3). Only introduction of a second substituent at the α -carbon led to a slightly lower yield of 63% for **2n**. The methyl substituent probably sterically hinders the nucleophilic attack on the pyridine's γ -carbon. When acetyl chloride or bromo acetyl bromide were used as acylating agents, no product could be isolated, although consumption of the starting material was observed.


TABLE 3. Various acyl halides employed in the rearrangement



entry	acyl chloride	product	R	yield [%]
1		2a	Cl	79
2		2n	Cl, Me	63
3		2o	OMe	97
4		2p	OPh	92
5		2q	OBn	83

For the presented rearrangement reaction the following mechanism is proposed (Scheme 2). First the ketene, which is formed *in situ* by dehydrohalogenation of an acyl chloride with triethylamine, is attacked on its electrophilic carbon by the amine nitrogen of substrate **D** to form the intermediate **E**. Then, intramolecular π -orbital interaction between the enolate α -carbon and the pyridine ipso-carbon results in the formation of the four-membered spiro- β -lactam transition

state **F**. Finally, rearomatization of the pyridine leads to breakage of the weaker C-N bond of the spiro- β -lactam and results in formation of the pyridin-4-yl α -substituted acetamide **G**. The nucleophilic attack on the pyridine γ -carbon by the enol is possibly facilitated by ortho substitution with an electron withdrawing halide. Moreover, the electronegative nitrogen of the pyridine ring lowers the energy of the π -system's LUMO and increases the electrophilicity of the γ -position.³⁻⁸ This effect could be enhanced by either catalytic acylation (excess of acyl chloride) or protonation (via the trialkylammonium salts resulting from the ketene formation, that can act as Brønsted acid catalysts)¹⁸ of the pyridine nitrogen atom. This might further decrease the electron density of the aromatic ring, and ultimately lead to a higher susceptibility of the γ -carbon towards a nucleophile. A phenyl analogue of the pyridine precursor **1a**, *N*-benzyl-2-chloro-4-nitroaniline, whose γ -carbon is highly activated through strongly electron withdrawing ortho-chloro and para-nitro substituents, does not undergo the rearrangement under the applied standard reaction conditions.

SCHEME 2. Proposed mechanism for the rearrangement of 4-amino-3-halo-pyridines

Anand and co-workers have recently reported a [2+2] cycloaddition of cyclohexanone imines and ketenes leading to the formation of spiro- β -lactams.²² The corresponding analogs cannot be isolated from our rearrangement reactions since rearomatization of the pyridine ring induces cleavage of the C-N bond and leads to the open structure. However, the formation of these spirocyclic- β -lactams by an analogous pathway provides further evidence for the inclusion of transition state **F** in our proposed mechanism.²³

In summary, we have described the rearrangement of 3-halo-4-amino-pyridines when treated with triethylamine and acyl chlorides, to yield pyridin-4-yl-acetamides. The mild reaction conditions and the simple workup allow a straightforward and scalable synthesis (on a multi-gram-scale **2a** was obtained in 50% yield) of pyridin-4-yl α -substituted acetamides. These molecules represent promising precursor molecules for the synthesis of branched aryl

acetamides, which might be employed in future biological screening campaigns and are yet to be exploited structures.

EXPERIMENTAL SECTION

General information. NMR spectra were recorded on a 500 MHz spectrometer (500 MHz ^1H , 125 MHz ^{13}C) at 25 °C. Chemical shifts are reported in ppm (δ) referenced to the NMR solvent, coupling constants (J) in Hz.²⁴ Flash column chromatography was performed on silica gel (60 Å mesh). High-resolution mass spectrometry (HRMS) was conducted using a quadrupole-time-of-flight (QTOF) hybrid mass spectrometer system coupled with an ultra-performance liquid chromatography (UPLC) system. Microwave reactions were carried out in the microwave reactor Biotage Initiator Eight (single-mode reactor, temperature control via IR).

General procedure A for the synthesis of 2,4-dimethoxybenzyl-pyridin-4-amines. The reductive aminations were conducted according to literature using the corresponding aminopyridine (1 equiv), benzaldehyde (3 equiv), acetic acid (3 equiv), sodium triacetoxyborohydride (3 equiv), and $\text{C}_2\text{H}_4\text{Cl}_2$ (20 mL).^{25,26} Some reactions required refluxing at 80 °C. The crude product was purified by silica gel flash chromatography (1-8 % MeOH/ CH_2Cl_2 or 10-80 % EtOAc/Hexanes).

General procedure B for the synthesis of 2,4-dimethoxybenzyl-pyridin-4-amines. The copper-catalyzed amination of aryl halides was conducted according to literature.²⁷ Alternatively, some products were obtained through irradiation in a microwave reactor at 100 °C for 60 min at the absorption level “High”. The crude product was purified by silica gel flash chromatography (1-8 % MeOH/ CH_2Cl_2 or 10-80 % EtOAc/Hexanes).

General procedure C for the rearrangement reaction of pyridin-4-amines. A 5 mL reaction vial was charged with the corresponding secondary pyridin-4-amine (0.25 mmol), TEA (3 equiv), and THF (2 mL). Then, the corresponding acyl chloride was added dropwise (the more exothermic reactions required cooling to 0 °C), and the reaction mixture was stirred at rt. If LCMS indicated incomplete reaction, TEA (5 equiv) and the acyl chloride (2 equiv) were added in intervals of 1h twice and the reaction mixture was stirred over night before it was diluted with EtOAc and saturated NaHCO₃ (aq.). The aqueous layer was extracted with EtOAc (3x), and the combined organic layers were concentrated and purified by silica gel flash chromatography (1-8 % MeOH/CH₂Cl₂ or 10-80 % EtOAc/Hexanes).

3-chloro-*N*-(2,4-dimethoxybenzyl)pyridin-4-amine (1a). A; yellow oil (9.47 g, 83%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 7.97 (d, *J* = 5.6 Hz, 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 6.73 (t, *J* = 6.1 Hz, 1H), 6.58 (d, *J* = 2.4 Hz, 1H), 6.48-6.45 (m, 2H), 4.32 (d, *J* = 6.2 Hz, 2H), 3.84 (s, 3H), 3.73 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 159.7, 157.7, 148.9, 148.2, 147.5, 128.0, 117.7, 115.7, 106.2, 104.6, 98.4, 55.4, 55.1, 39.9. HRMS (ESI⁺-QTOF) *m/z* calcd for C₁₄H₁₆ClN₂O₂ ([M+H]⁺): 279.0900, found: 279.0892.

***N*-(2,4-dimethoxybenzyl)-3-fluoropyridin-4-amine (1b).** A; colourless oil (0.452 g, 37%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.08 (d, *J* = 3.8 Hz, 1H), 7.88 (d, *J* = 5.4 Hz, 1H), 7.06 (d, *J* = 8.4 Hz, 1H), 6.91 (t, *J* = 6.2 Hz, 1H), 6.57 (d, *J* = 2.3 Hz, 1H), 6.52-6.45 (m, 2H), 4.26 (d, *J* = 6.2 Hz, 2H), 3.83 (s, 3H), 3.73 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 159.7, 157.7, 148.6 (¹*J*_{C-F} = 245 Hz), 146.2 (⁴*J*_{C-F} = 4.4 Hz), 142.0 (³*J*_{C-F} = 9.9 Hz), 134.7 (⁴*J*_{C-F} = 19 Hz), 128.2, 118.0, 106.7, 104.5, 98.3, 55.4, 55.1, 39.6. HRMS (ESI⁺-QTOF) *m/z* calcd for C₁₄H₁₆FN₂O₂ ([M+H]⁺): 263.1196, found: 263.1187.

3-bromo-*N*-(2,4-dimethoxybenzyl)pyridin-4-amine (1c). A; colourless oil (0.491 g, 50%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.26 (s, 1H), 7.99 (d, $J = 5.6$ Hz, 1H), 7.03 (d, $J = 8.4$ Hz, 1H), 6.58 (d, $J = 2.4$ Hz, 1H), 6.51 (t, $J = 6.1$ Hz, 1H), 6.48-6.44 (m, 2H), 4.32 (d, $J = 6.2$ Hz, 2H), 3.84 (s, 3H), 3.73 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 159.8, 157.7, 150.2, 149.8, 148.7, 128.1, 117.6, 106.6, 104.6, 98.4, 55.5, 55.1, 40.2. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{14}\text{H}_{16}\text{BrN}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): 323.0395, found: 323.0396.

***N*-(2,4-dimethoxybenzyl)-3-iodopyridin-4-amine (1d).** A; colourless oil (427 mg, 51%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.41 (s, 1H), 7.97 (d, $J = 5.6$ Hz, 1H), 7.04 (d, $J = 8.3$ Hz, 1H), 6.58 (d, $J = 4.2$ Hz, 1H), 6.46 (dd, $J = 2.4, 8.3$ Hz, 1H), 6.40 (d, $J = 5.7$ Hz, 1H), 6.11 (t, $J = 6.0$ Hz, 1H), 4.33 (d, $J = 6.1$ Hz, 2H), 3.84 (s, 3H), 3.73 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 159.8, 157.8, 155.9, 152.2, 149.0, 128.3, 117.6, 106.2, 104.5, 98.4, 83.3, 55.5, 55.1, 40.6. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{14}\text{H}_{16}\text{IN}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): 371.0257, found: 371.0241.

***N*-(2,4-dimethoxybenzyl)-3-methylpyridin-4-amine (1e).** A; colourless oil (1.28 g, 25%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 7.89 (s, 1H), 7.87 (s, 1H), 7.02 (d, $J = 8.3$ Hz, 1H), 6.57 (d, $J = 2.4$ Hz, 1H), 6.50 (dd, $J = 2.4, 8.4$ Hz, 1H), 6.26-6.21 (m, 2H), 4.27 (d, $J = 6.1$ Hz, 2H), 3.84 (s, 3H), 3.72 (s, 3H), 2.08 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 159.5, 157.6, 151.5, 148.7, 147.9, 127.9, 118.4, 116.7, 104.4, 104.2, 98.3, 55.4, 55.1, 14.4. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): 259.1447, found: 259.1437.

4-((2,4-dimethoxybenzyl)amino)nicotinonitrile (1f). B; white solid (328 mg, 32%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.48 (s, 1H), 8.17 (d, $J = 6.3$ Hz, 1H), 7.71 (t, $J = 5.8$ Hz, 1H), 7.07 (d, $J = 8.3$ Hz, 1H), 6.60-6.58 (m, 2H), 6.48 (dd, $J = 2.4, 8.3$ Hz, 1H), 4.37 (d, $J = 6.4$ Hz, 2H), 3.83 (s, 3H), 3.73 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 159.9, 157.7, 154.3, 152.7, 150.9, 128.3,

117.0, 116.1, 106.2, 104.7, 98.4, 92.7, 55.5, 55.2, 40.2. HRMS (ESI⁺-QTOF) m/z calcd for C₁₅H₁₆N₃O₂ ([M+H]⁺): 270.1243, found: 270.1230.

Methyl 4-((2,4-dimethoxybenzyl)amino)nicotinate (1g). A; white solid (596 mg, 20%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.72 (s, 1H), 8.49 (bs, 1H), 8.19 (d, *J* = 6.3 Hz, 1H), 7.71 (d, *J* = 8.3 Hz, 1H), 7.17 (d, *J* = 8.2 Hz, 1H), 6.80 (d, *J* = 6.4 Hz, 1H), 6.48 (dd, *J* = 2.3, 8.3 Hz, 1H), 4.40 (d, *J* = 5.9 Hz, 2H), 3.83 (s, 6H), 3.73 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 167.1, 160.2, 158.0, 154.2, 150.5, 150.3, 129.2, 117.2, 106.8, 106.7, 104.6, 98.6, 55.5, 55.2, 51.9, 40.7. HRMS (ESI⁺-QTOF) m/z calcd for C₁₆H₁₉N₂O₄ ([M+H]⁺): 303.1345, found: 303.1331.

2-chloro-*N*-(2,4-dimethoxybenzyl)pyridin-4-amine (1h). A; pale yellow oil (0.631 g, 55%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.78 (d, *J* = 5.9 Hz, 1H), 7.19 (t, *J* = 5.5 Hz, 1H), 7.11 (d, *J* = 8.3 Hz, 1H), 6.58 (d, *J* = 2.4 Hz, 1H), 6.51-6.48 (m, 3H), 4.16 (d, *J* = 5.8 Hz, 2H), 3.81 (s, 3H), 3.74 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 160.0, 158.0, 155.9, 150.9, 148.8, 129.1, 117.8, 107.3, 105.1, 104.5, 98.4, 55.4, 55.2, 40.1. HRMS (ESI⁺-QTOF) m/z calcd for C₁₄H₁₆ClN₂O₂ ([M+H]⁺): 279.0900, found: 279.0893.

4-((2,4-dimethoxybenzyl)amino)picolinonitrile (1i). B; colourless crystals (504 mg, 26%); mp 119-121 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.09 (d, *J* = 5.9 Hz, 1H), 7.38 (t, *J* = 5.6 Hz, 1H), 7.13 (d, *J* = 8.3 Hz, 1H), 7.05 (d, *J* = 1.9 Hz, 1H), 6.72 (bs, 1H), 6.59 (d, *J* = 2.4 Hz, 1H), 6.49 (dd, *J* = 2.4, 8.3 Hz, 1H), 4.19 (d, *J* = 5.6 Hz, 2H), 3.81 (s, 3H), 3.74 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 160.1, 158.1, 153.9, 150.5, 132.7, 129.3, 126.3, 122.0, 118.2, 117.4, 104.5, 98.5, 55.4, 55.2, 40.1. HRMS m/z (ESI⁺-QTOF) calcd for C₁₅H₁₆N₃O₂ ([M+H]⁺): 270.1243, found: 270.1231.

3-chloro-*N*-(2,4,6-trimethoxybenzyl)pyridin-4-amine (1j). A; white solid (81 mg, 3 %). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.15-8.07 (m, 2H), 6.83 (d, J = 5.5 Hz, 1H), 6.26 (s, 2H), 5.69 (t, J = 5.8 Hz, 1H), 4.30 (d, J = 6.0 Hz, 2H), 3.83 (s, 6H), 3.77 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 160.8, 158.9, 148.7, 148.4, 147.5, 115.7, 106.1, 105.5, 91.0, 55.9, 55.3, 35.0. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{15}\text{H}_{18}\text{ClN}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 309.1006, found: 309.1013.

3-chloro-*N*-(2-methoxybenzyl)pyridin-4-amine (1k). A; white solid (1.32 g, 55 %). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.21 (s, 1H), 8.00 (d, J = 5.6 Hz, 1H), 7.27 (m, 1H), 7.13 (dd, J = 7.4, 1.3 Hz, 1H), 7.06 (d, J = 8.1 Hz, 1H), 6.92 (td, J = 7.4, 0.6 Hz, 1H), 6.87 (t, J = 6.1 Hz, 1H), 6.47 (d, J = 5.7 Hz, 1H), 4.45 (d, J = 6.1 Hz, 2H), 3.90 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 157.6, 149.9, 149.2, 148.5, 129.1, 127.9, 126.5, 121.2, 116.6, 111.6, 107.1, 56.3, 41.1. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{13}\text{H}_{14}\text{ClN}_2\text{O}$ ($[\text{M}+\text{H}]^+$): 249.0795, found: 249.0791.

3-chloro-*N*-(4-nitrobenzyl)pyridin-4-amine (1l). A; off-white solid (53 mg, 3 %). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.22-8.20 (m, 3H), 7.97 (d, J = 5.6 Hz, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.26 (t, J = 6.1 Hz, 1H), 6.48 (d, J = 5.5 Hz, 1H), 4.61 (d, J = 6.3 Hz, 2H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 148.7, 148.3, 147.8, 147.0, 146.6, 127.9, 123.6, 115.9, 106.3, 44.6. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{12}\text{H}_{11}\text{ClN}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): 264.0540, found: 264.0533.

3-chloro-*N*-(4-chlorobenzyl)pyridin-4-amine (1m). A; white solid (328 mg, 15%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.16 (s, 1H), 7.96 (dd, J = 0.5, 5.7 Hz, 1H), 7.40-7.33 (m, 4H), 7.13 (t, J = 6.3 Hz, 1H), 6.49 (d, J = 5.6 Hz, 1H), 4.45 (d, J = 6.3 Hz, 2H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 148.8, 148.2, 147.7, 137.8, 131.4, 128.7, 128.4, 115.8, 106.3, 44.3. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{12}\text{H}_{11}\text{Cl}_2\text{N}_2$ ($[\text{M}+\text{H}]^+$): 253.0289, found: 253.0299.

***N*-benzyl-3-chloropyridin-4-amine (1n).** A; white solid (422 mg, 22%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.15 (s, 1H), 7.95 (d, *J* = 5.6 Hz, 1H), 7.32 (d, *J* = 4.4 Hz, 4H), 7.21-7.25 (m, 1H), 7.09 (t, *J* = 6.3 Hz, 1H), 6.50 (d, *J* = 5.6 Hz, 1H), 4.46 (d, *J* = 6.3 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 149.0, 148.2, 147.6, 138.7, 128.4, 126.9, 126.7, 115.7, 106.4, 45.0. HRMS (ESI⁺-QTOF) *m/z* calcd for C₁₂H₁₂ClN₂ ([M+H]⁺): 219.0689, found: 219.0691.

3-chloro-*N*-phenylpyridin-4-amine (1o).²⁸

3-chloro-*N*-propylpyridin-4-amine (1p). A; yellow oil (740 mg, 53%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 8.03 (d, *J* = 5.6 Hz, 1H), 6.63 (d, *J* = 5.6 Hz, 1H), 6.30 (t, *J* = 5.6 Hz, 1H), 3.17-3.13 (m, 2H), 1.58-1.51 (m, 2H), 0.88 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 149.0, 148.3, 147.6, 115.5, 105.7, 48.4, 21.4, 11.1. HRMS (ESI⁺-QTOF) *m/z* calcd for C₈H₁₂ClN₂ ([M+H]⁺): 171.0689, found: 171.0678.

***N*-(but-3-en-1-yl)-3-chloropyridin-4-amine (1q).** B; yellow oil (128 mg, 32%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.14 (s, 1H), 8.05 (d, *J* = 5.7 Hz, 1H), 6.68 (d, *J* = 5.7 Hz, 1H), 6.23 (t, *J* = 5.6 Hz, 1H), 5.87-5.75 (m, 1H), 5.13-5.08 (m, 1H), 5.06-5.03 (m, 1H), 3.27 (q, *J* = 6.1, 6.9 Hz, 2H), 2.34-2.29 (m, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 148.8, 148.3, 147.6, 135.7, 116.7, 115.6, 105.8, 41.0, 32.5. HRMS (ESI⁺-QTOF) *m/z* calcd for C₉H₁₂ClN₂ ([M+H]⁺): 183.0689, found: 183.0681.

2-chloro-2-(3-chloropyridin-4-yl)-*N*-(2,4-dimethoxybenzyl)acetamide (2a). C; white solid (3.8 g, 79 %); mp 145-147 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.87 (t, *J* = 5.7 Hz, 1H), 8.68 (s, 1H), 8.61 (d, *J* = 5.1 Hz, 1H), 7.70 (d, *J* = 5.1 Hz, 1H), 7.10 (d, *J* = 8.3 Hz, 1H), 6.55 (d, *J* = 2.4 Hz, 1H), 6.49 (dd, *J* = 2.4, 8.3 Hz, 1H), 5.92 (s, 1H), 4.27-4.18 (m, 2H), 3.76 (s, 3H), 3.74 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 164.8, 160.0, 157.8, 149.1, 148.6, 142.9, 130.0, 129.2,

124.2, 117.8, 104.3, 98.3, 55.4, 55.2, 54.8, 37.9. HRMS (ESI⁺-QTOF) m/z calcd for C₁₆H₁₇Cl₂N₂O₃ ([M+H]⁺): 355.0616, found: 355.0600.

2-chloro-*N*-(2,4-dimethoxybenzyl)-2-(3-fluoropyridin-4-yl)acetamide (2b). C; purification by preparative HPLC (5-95 % MeCN/H₂O, 15 min); white solid (8 mg, 12 %); mp 119-122 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (d, *J* = 1.4 Hz, 1H), 8.44 (d, *J* = 5.0 Hz, 1H), 7.37-7.36 (m, 2H), 7.19 (d, *J* = 8.1 Hz, 1H), 6.50 (d, *J* = 2.5 Hz, 1H), 6.45 (dd, *J* = 2.5, 8.1 Hz, 1H), 5.56 (s, 1H), 4.50-4.41 (m, 2H), 3.87 (s, 3H), 3.82 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.66, 161.18, 158.90, 157.22 (d, ¹*J*_{C-F} = 259.5 Hz, 1C), 145.45 (d, ⁴*J*_{C-F} = 5.4 Hz, 1C), 138.0 (d, ²*J*_{C-F} = 24.5 Hz, 1C), 134.7 (d, ³*J*_{C-F} = 10.9 Hz, 1C), 130.9, 124.0, 117.7, 104.3, 99.0, 55.7, 55.6, 52.9 (d, ³*J*_{C-F} = 1.8 Hz, 1C), 40.4. HRMS (ESI⁺-QTOF) m/z calcd for C₁₆H₁₇ClFN₂O₃ ([M+H]⁺): 339.0912, found: 339.0905.

2-(3-bromopyridin-4-yl)-2-chloro-*N*-(2,4-dimethoxybenzyl)acetamide (2c). C; recrystallization (CH₂Cl₂/Hexanes); off-white solid (59 mg, 84 %); mp 155-157 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.90 (d, *J* = 5.6 Hz, 1H), 8.78 (s, 1H), 8.62 (d, *J* = 5.2 Hz, 1H), 7.69 (d, *J* = 4.9 Hz, 1H), 7.10 (d, *J* = 8.3 Hz, 1H), 6.55 (d, *J* = 2.4 Hz, 1H), 6.48 (dd, *J* = 2.4, 8.3 Hz, 1H), 5.84 (s, 1H), 4.27-4.18 (m, 2H), 3.76 (s, 3H), 3.74 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.7, 160.0, 157.8, 151.7, 149.0, 144.5, 129.2, 124.6, 121.1, 117.8, 104.3, 98.3, 57.1, 55.4, 55.2, 37.9. HRMS (ESI⁺-QTOF) m/z calcd for C₁₆H₁₇BrClN₂O₃ ([M+H]⁺): 399.0111, found: 399.0103.

2-chloro-*N*-(2,4-dimethoxybenzyl)-2-(3-iodopyridin-4-yl)acetamide (2d). C; recrystallization (MeOH); off-white solid (24 mg, 29 %); mp 158-160 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.94 (s, 1H), 8.92 (t, *J* = 5.5 Hz, 1H), 8.58 (d, *J* = 5.0 Hz, 1H), 7.64 (d, *J* = 5.0 Hz, 1H), 7.11 (d, *J* = 8.3 Hz, 1H), 6.55 (d, *J* = 2.5 Hz, 1H), 6.48 (dd, *J* = 2.4, 6.0 Hz, 1H), 5.66 (s, 1H), 4.27-4.18 (m,

2H), 3.76 (s, 3H), 3.74 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 164.8, 159.9, 157.8, 157.4, 149.2, 147.7, 129.2, 124.4, 117.8, 104.3, 99.1, 98.3, 61.4, 55.4, 55.2, 37.8. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{16}\text{H}_{17}\text{IClN}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 446.9972, found: 446.9974.

2-chloro-*N*-(2,4-dimethoxybenzyl)-2-(3-methylpyridin-4-yl)acetamide (2e). C; clear oil (12 mg, 10 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.68 (d, $J = 5.5$ Hz, 1H), 8.44 (d, $J = 5.1$ Hz, 1H), 8.42 (s, 1H), 7.48 (d, $J = 5.1$ Hz, 1H), 7.06 (d, $J = 8.4$ Hz, 1H), 6.54 (d, $J = 2.1$ Hz, 1H), 6.47 (dd, $J = 2.1, 8.3$ Hz, 1H), 5.79 (s, 1H), 4.25-4.16 (m, 2H), 3.75 (s, 3H), 3.73 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 166.0, 160.5, 158.4, 151.4, 148.2, 144.2, 131.6, 129.8, 122.5, 118.4, 104.8, 98.8, 56.1, 55.9, 55.7, 38.4, 15.9. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{ClN}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 335.1162, found: 335.1150.

2-chloro-2-(3-chloropyridin-4-yl)-*N*-(2,4,6-trimethoxybenzyl)acetamide (2f). C; off-white solid (19 mg, 63 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.70 (s, 1H), 8.61 (d, $J = 5.1$ Hz, 1H), 8.37 (t, $J = 4.6$ Hz, 1H), 7.70 (d, $J = 5.1$ Hz, 1H), 6.24 (s, 2H), 5.85 (s, 1H), 4.29-4.18 (m, 2H), 3.78 (s, 3H), 3.75 (s, 6H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 164.2, 160.8, 159.1, 149.1, 148.5, 143.0, 130.1, 124.1, 104.8, 90.7, 55.7, 55.3, 54.7, 32.2. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{17}\text{H}_{19}\text{Cl}_2\text{N}_2\text{O}_4$ ($[\text{M}+\text{H}]^+$): 385.0722, found: 385.0720.

2-chloro-2-(3-chloropyridin-4-yl)-*N*-(2-methoxybenzyl)acetamide (2g). C; yellow solid (91 mg, 69 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.96 (m, 1H), 8.68 (s, 1H), 8.61 (d, $J = 5.1$ Hz, 1H), 7.70 (d, $J = 5.1$ Hz, 1H), 7.26 (m, 1H), 7.18 (dd, $J = 7.4, 1.6$ Hz, 1H), 6.99 (d, $J = 8.2$ Hz, 1H), 6.91 (td, $J = 7.4$ Hz, 0.9, 1H), 5.95 (s, 1H), 4.30 (m, 2H), 3.75 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 165.0, 156.7, 149.1, 148.6, 142.8, 130.0, 128.4, 128.0, 125.6, 124.2, 120.1, 110.6,

55.3, 54.9, 38.1. HRMS (ESI⁺-QTOF) m/z calcd for C₁₅H₁₅Cl₂N₂O₂ ([M+H]⁺): 325.0511, found: 325.0496.

2-chloro-2-(3-chloropyridin-4-yl)-N-(4-nitrobenzyl)acetamide (2h). C; white solid (10 mg, 34 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.37 (t, *J* = 5.8 Hz, 1H), 8.70 (s, 1H), 8.62 (d, *J* = 5.1 Hz, 1H), 8.22 (d, *J* = 8.4 Hz, 2H), 7.68 (d, *J* = 5.0 Hz, 1H), 7.55 (d, *J* = 8.4 Hz, 2H), 6.00 (s, 1H), 4.49 (d, *J* = 6.1 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.5, 149.2, 148.7, 146.6, 146.5, 142.8, 130.0, 128.3, 124.3, 123.5, 55.1, 42.4. HRMS (ESI⁺-QTOF) m/z calcd for C₁₄H₁₂Cl₂N₃O₃ ([M+H]⁺): 340.0256, found: 340.0255.

2-chloro-N-(4-chlorobenzyl)-2-(3-chloropyridin-4-yl)acetamide (2i). C; white solid (43 mg, 53 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.20 (t, *J* = 5.8 Hz, 1H), 8.68 (s, 1H), 8.60 (d, *J* = 5.2 Hz, 1H), 7.67 (d, *J* = 5.2 Hz, 1H), 7.41-7.38 (m, 2H), 7.30-7.27 (m, 2H), 5.94 (s, 1H), 4.33 (d, *J* = 6.1 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.2, 149.2, 148.6, 142.8, 137.5, 131.6, 130.0, 129.2, 128.3, 124.3, 55.0, 42.2. HRMS (ESI⁺-QTOF) m/z calcd for C₁₄H₁₂Cl₃N₂O ([M+H]⁺): 329.0015, found: 329.0009.

N-benzyl-2-chloro-2-(3-chloropyridin-4-yl)acetamide (2j). C; white solid (44 mg, 54 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.18 (t, *J* = 5.6 Hz, 1H), 8.68 (s, 1H), 8.61 (d, *J* = 5.1 Hz, 1H), 7.69 (d, *J* = 5.1 Hz, 1H), 7.35-7.24 (m, 5H), 5.94 (s, 1H), 4.35 (d, *J* = 6.1 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.5, 150.1, 148.5, 143.6, 137.2, 131.6, 129.1, 128.2, 128.15, 123.8, 56.1, 44.6. HRMS (ESI⁺-QTOF) m/z calcd for C₁₄H₁₃Cl₂N₂O ([M+H]⁺): 295.0394, found: 295.0394.

2-chloro-2-(3-chloropyridin-4-yl)-N-phenylacetamide (2k). C; white solid (43 mg, 53 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.74 (s, 1H), 8.71 (s, 1H), 8.64 (d, *J* = 5.0 Hz, 1H), 7.77 (d, *J* =

5.1 Hz, 1H), 7.60-7.57 (m, 2H), 7.37-7.33 (m, 2H), 7.15-7.11 (m, 1H), 6.06 (s, 1H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 163.5, 149.1, 148.7, 142.3, 138.0, 130.0, 128.9, 124.4, 124.1, 119.6, 55.7. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{13}\text{H}_{11}\text{Cl}_2\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$): 281.0248, found: 281.0234.

2-chloro-2-(3-chloropyridin-4-yl)-*N*-propylacetamide (2l). C; colourless oil (63 mg, 35 %). ^1H NMR (500 MHz, DMSO- d_6) δ 8.67 (s, 1H), 8.65 (d, J = 5.6 Hz, 1H), 8.60 (d, J = 5.0 Hz, 1H), 7.68 (d, J = 5.0 Hz, 1H), 5.84 (s, 1H), 3.09 (q, J = 5.9, 6.7 Hz, 2H), 1.49-1.42 (m, 2H), 0.84 (t, J = 7.5 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 164.8, 149.1, 148.6, 143.0, 129.2, 124.2, 55.0, 41.0, 20.9, 11.2. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{10}\text{H}_{13}\text{Cl}_2\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$): 247.0405, found: 247.0395.

***N*-(but-3-en-1-yl)-2-chloro-2-(3-chloropyridin-4-yl)acetamide (2m).** C; colourless oil (24 mg, 32 %). ^1H NMR (500 MHz, DMSO- d_6) δ 8.67 (s, 1H), 8.66 (t, J = 6.0 Hz, 1H), 8.60 (d, J = 5.0 Hz, 1H), 7.66 (d, J = 5.0 Hz, 1H), 5.84 (s, 1H), 5.80-5.72 (m, 1H), 5.05 (dq, 1.6, 2.0, 17.0 Hz, 1H), 5.02-4.99 (m, 1H), 3.22-3.18 (m, 2H), 2.22-2.19 (m, 2H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 164.9, 149.1, 148.6, 143.0, 136.9, 130.0, 124.2, 116.5, 55.0, 39.7, 33.9. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{11}\text{H}_{13}\text{Cl}_2\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$): 259.0405, found: 259.0395.

2-chloro-2-(3-chloropyridin-4-yl)-*N*-(2,4-dimethoxybenzyl)propanamide (2n). C; white solid (99 mg, 63 %). ^1H NMR (500 MHz, DMSO- d_6) δ 8.62 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.38 (t, J = 5.9 Hz, 1H), 7.79 (d, J = 5.2 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.54 (d, J = 2.8 Hz, 1H), 6.48 (dd, J = 2.3, 8.3 Hz, 1H), 4.24 (m, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 2.13 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 168.3, 159.7, 157.6, 150.1, 148.6, 146.9, 130.2, 128.5, 122.8, 118.3, 104.2, 98.1, 68.8, 55.3, 55.1, 38.0, 28.5. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{17}\text{H}_{19}\text{Cl}_2\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 369.0773, found: 369.0768.

2-(3-chloropyridin-4-yl)-N-(2,4-dimethoxybenzyl)-2-methoxyacetamide (2o). C; white solid (194 mg, 97 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.63 (s, 1H), 8.55 (d, $J = 4.9$ Hz, 1H), 8.47 (t, $J = 6.0$ Hz, 1H), 7.46 (d, $J = 4.9$ Hz, 1H), 7.05 (d, $J = 8.3$ Hz, 1H), 6.54 (d, $J = 2.4$ Hz, 1H), 6.46 (dd, $J = 2.4, 8.3$ Hz, 1H), 5.09 (s, 1H), 4.21 (d, $J = 6.0$ Hz, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 3.34 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 167.3, 159.8, 157.7, 149.0, 148.2, 144.2, 130.8, 128.7, 123.3, 118.4, 104.2, 98.2, 79.2, 57.6, 55.3, 55.2, 37.1. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{ClN}_2\text{O}_4$ ($[\text{M}+\text{H}]^+$): 351.1112, found: 351.1096.

2-(3-chloropyridin-4-yl)-N-(2,4-dimethoxybenzyl)-2-phenoxyacetamide (2p). C; off-white solid (196 mg, 92 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.81 (t, $J = 5.7$ Hz, 1H), 8.67 (s, 1H), 8.54 (d, $J = 5.0$ Hz, 1H), 7.55 (d, $J = 5.0$ Hz, 1H), 7.29 (t, $J = 8.1$ Hz, 2H), 6.85-7.05 (m, 4H), 6.53 (d, $J = 2.3$ Hz, 1H), 6.44 (dd, $J = 2.3, 8.3$ Hz, 1H), 6.06 (s, 1H), 4.18-4.30 (m, 2H), 3.75 (s, 3H), 3.73 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 166.1, 159.8, 157.7, 156.4, 149.2, 148.3, 143.3, 130.5, 129.6, 128.8, 123.3, 122.0, 118.2, 115.5, 104.2, 98.2, 75.2, 55.4, 55.2, 37.3. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{22}\text{H}_{22}\text{ClN}_2\text{O}_4$ ($[\text{M}+\text{H}]^+$): 413.1268, found: 413.1263.

2-(benzyloxy)-2-(3-chloropyridin-4-yl)-N-(2,4-dimethoxybenzyl)acetamide (2q). C; white solid (159 mg, 83 %). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.63 (s, 1H), 8.56 (d, $J = 4.9$ Hz, 1H), 8.49 (t, $J = 5.9$ Hz, 1H), 7.54 (d, $J = 4.9$ Hz, 1H), 7.40-7.25 (m, 5H), 7.07 (d, $J = 8.5$ Hz, 1H), 6.55 (d, $J = 2.2$ Hz, 1H), 6.46 (dd, $J = 2.2$ Hz, $J = 8.5$ Hz, 1H), 5.75 (CH_2Cl_2), 5.30 (s, 1H), 4.65-4.50 (m, 2H), 4.26 (m, 2H), 3.76 (s, 3H), 3.74 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 167.3, 159.8, 157.7, 149.0, 148.2, 144.3, 137.1, 130.8, 128.7, 128.3, 128.2, 127.9, 127.9, 127.7, 123.4, 118.5, 104.2, 98.3, 77.2, 71.5, 55.3, 55.2, 37.3. HRMS (ESI^+ -QTOF) m/z calcd for $\text{C}_{15}\text{H}_{15}\text{Cl}_2\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): 325.0511, found: 325.0496. HRMS m/z calcd for $\text{C}_{23}\text{H}_{24}\text{ClN}_2\text{O}_4$ ($[\text{M}+\text{H}]^+$): 427.1425, found: 427.1405.

***N*-(2,4-dimethoxybenzyl)-2-(3-fluoropyridin-4-yl)-2-phenoxyacetamide (2r).** C; preparative HPLC (5-95 % MeCN/H₂O, 15 min); white solid (6 mg, 14 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.76 (t, *J* = 5.8 Hz, 1H), 8.62 (d, *J* = 1.4 Hz, 1H), 8.47 (d, *J* = 5.0 Hz, 1H), 7.60 (t, *J* = 5.5 Hz, 1H), 7.32-7.28 (m, 2H), 7.03-6.98 (m, 4H), 6.53 (d, *J* = 2.4 Hz, 1H), 6.43 (dd, *J* = 2.4, 8.3 Hz, 1H), 6.09 (s, 1H), 4.27-4.20 (m, 2H), 3.74 (s, 3H), 3.73 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 166.5, 159.8, 157.6, 156.8 (d, ¹*J*_{C-F} = 257.2 Hz, 1C), 156.4, 146.1 (d, ⁴*J*_{C-F} = 5.0 Hz, 1C), 138.0 (d, ²*J*_{C-F} = 23.7 Hz, 1C), 132.7 (d, ³*J*_{C-F} = 11.7 Hz, 1C), 129.6, 128.6, 123.1, 122.0, 118.2, 115.6, 104.2, 98.2, 72.5, 55.3, 55.2, 37.2. HRMS (ESI⁺-QTOF) *m/z* calcd for C₂₂H₂₂FN₂O₄ ([M+H]⁺): 397.1564, found: 397.1545.

2-chloro-*N*-(2,4-dimethoxybenzyl)-*N*-(3-fluoropyridin-4-yl)acetamide (3a). C; 1:2.5 mixture of **3a** and the rearranged product **2b**. The ¹H NMR of the mixture was collected and confirms identity of **3a**, however the product could not be isolated.

2-chloro-*N*-(3-cyanopyridin-4-yl)-*N*-(2,4-dimethoxybenzyl)acetamide (3b). C; colourless oil (14 mg, 14 %). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.94 (s, 1H), 8.47 (d, *J* = 6.1 Hz, 1H), 7.17 (d, *J* = 6.3 Hz, 1H), 6.82 (d, *J* = 8.6 Hz, 1H), 6.48 (d, *J* = 8.5 Hz, 1H), 6.32 (dd, *J* = 8.3, 8.6 Hz, 1H), 5.53 (s, 2H), 5.43 (s, 2H), 3.92 (s, 3H), 3.74 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 160.6, 159.4, 157.7, 150.0, 145.8, 144.7, 143.1, 128.6, 116.2, 110.4, 109.9, 104.9, 102.9, 98.7, 55.8, 55.6, 40.6. HRMS (ESI⁺-QTOF) *m/z* calcd for C₁₇H₁₇ClN₃O₃ ([M+H]⁺): 346.0958, found: 346.0946.

2-chloro-*N*-(2-chloropyridin-4-yl)-*N*-(2,4-dimethoxybenzyl)acetamide (3c). C; brown oil (33 mg, 47%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.36 (d, *J* = 5.4 Hz, 1H), 7.53 (d, *J* = 1.7 Hz, 1H), 7.34 (dd, *J* = 1.85, 4.4 Hz, 1H), 7.10 (d, *J* = 8.3 Hz, 1H), 6.47 (d, *J* = 2.2 Hz, 1H), 6.43 (dd, *J* =

2.3, 8.5 Hz, 1H), 4.85 (s, 2H), 4.39 (s, 2H), 3.71 (s, 3H), 3.62 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 165.4, 160.2, 158.0, 151.2, 150.7, 150.5, 130.2, 122.3, 121.5, 115.6, 104.5, 98.3, 55.2, 55.1, 47.3, 42.9. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{16}\text{H}_{17}\text{Cl}_2\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 355.0616, found: 355.0618.

2-chloro-*N*-(2-cyanopyridin-4-yl)-*N*-(2,4-dimethoxybenzyl)acetamide (3d). C; off-white solid (63 mg, 98 %). ^1H NMR (500 MHz, DMSO- d_6) δ 8.69 (d, J = 5.4 Hz, 1H), 8.08 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 2.1, 5.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.47 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 2.4, 8.4 Hz, 1H), 4.88 (s, 2H), 4.44 (s, 2H), 3.71 (s, 3H), 3.61 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 165.5, 160.3, 158.0, 152.2, 149.8, 133.4, 130.3, 127.2, 125.8, 117.1, 115.5, 104.5, 98.3, 55.2, 55.1, 47.4, 43.0. HRMS (ESI $^+$ -QTOF) m/z calcd for $\text{C}_{17}\text{H}_{17}\text{ClN}_3\text{O}_3$ ($[\text{M}+\text{H}]^+$): 346.0958, found: 346.0955.

ASSOCIATED CONTENT

Supporting information

Crystallographic data (CIF) for **2a** and **2c** and ^1H and ^{13}C NMR spectra for all compounds are available. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding author

*E-mail: Rima.Alawar@oicr.on.ca

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

Dr. A. J. Lough (University of Toronto) is gratefully acknowledged for XRD analysis. We also would like to thank Dr. Ahmed Aman and Dr. Taira Kiyota for providing analytical chemistry

support and obtaining the high resolution mass spectra (HRMS) of all synthesized compounds.

We thank the Government of Ontario for funding which is provided through the Ontario Ministry of Research and Innovation.

REFERENCES

- (1) Moulay, S. *Chem. Educ. Res. Prac.* **2002**, 3, 33.
- (2) Snape, T. J. *Chem. Soc. Rev.* **2008**, 37, 2452.
- (3) Overman, L. E. *Tetrahedron* **2009**, 65, 6432.
- (4) Katritzky, A. R.; Pozharskii, A. F. *Handbook of Heterocyclic Chemistry*; 2 ed.; Pergamon Press, 2000.
- (5) Nowicki, J. *Molecules* **2000**, 5, 1033.
- (6) Commarieu, A.; Hoelderich, W.; Laffitte, J. A.; Dupont, M.-P. *J. Mol. Catal. A. Chem.* **2002**, 182–183, 137.
- (7) Dahlhoff, G.; Niederer, J. P. M.; Hoelderich, W. F. *Catal. Rev.* **2001**, 43, 381.
- (8) Anelli, P. L.; Brocchetta, M.; Cappelletti, E.; Ferraris, A.; Vincenzi, V. *The Open Org. Chem. J.* **2009**, 3, 35.
- (9) Evans, W. J.; Smiles, S. *J. Chem. Soc. (Resumed)* **1935**, 181.
- (10) March, J. *Advanced Organic Chemistry: Reactions, Mechanisms and Structure*; 4 ed.; John Wiley & Sons: New York, 1992.
- (11) Gilman, N. W.; Levitan, P.; Sternbach, L. H. *J. Org. Chem.* **1973**, 38, 373.
- (12) Plesniak, K.; Zarecki, A.; Wicha, J. *In Sulfur-Mediated Rearrangements II*; Schaumann, E., Ed.; Springer Berlin Heidelberg: **2007**; Vol. 275, p 163.
- (13) Tian, X.; Wu, R.-M. *ARKIVOC* **2011**, 118.

- (14) Truce, W. E.; Ray, W. J.; Norman, O. L.; Eickemeyer, D. B. *J. Am. Chem. Soc.* **1958**, *80*, 3625.
- (15) Mitchell, L. H.; Barvian, N. C. *Tetrahedron Letters* **2004**, *45*, 5669.
- (16) France, S.; Wack, H.; Taggi, A. E.; Hafez, A. M.; Wagerle, T. R.; Shah, M. H.; Dusich, C. L.; Lectka, T. *J. Am. Chem. Soc.* **2004**, *126*, 4245.
- (17) Erian, A. W.; Sherif, M. S.; Gaber, H. M. *Molecules* **2003**, *8*, 793.
- (18) Taggi, A. E.; Hafez, A. M.; Wack, H.; Young, B.; Ferraris, D.; Lectka, T. *J. Am. Chem. Soc.* **2002**, *124*, 6626.
- (19) Staudinger, H. *Justus Liebigs Ann. Chem.* **1907**, 356, 51.
- (20) Sauer, J. C. *J. Am. Chem. Soc.* **1947**, *69*, 2444.
- (21) Paull, D. H.; Weatherwax, A.; Lectka, T. *Tetrahedron* **2009**, *65*, 6771.
- (22) Anand, N.; Shah, B. A.; Kapoor, M.; Parshad, R.; Sharma, R. L.; Hundal, M. S.; Pannu, A. P.; Bharatam, P. V.; Taneja, S. C. *J. Org. Chem.* **2011**, *76*, 5999.
- (23) The work of Anand and co-workers suggests an alternative mechanism, in which the ketene may react with the tautomeric pyridonimine via a concerted [2+2] cycloaddition to directly form the 4-membered spirocyclic transition state **F**, excluding formation of intermediate **E**. Both mechanisms represent valid explanations for the discovered reaction and lead to the same product. However, the concerted mechanism appears to be less likely, since the aminopyridine is the predominant tautomeric form whereas the pyridonimine that would be required for a concerted [2+2] cycloaddition is the less favored tautomer.
- (24) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A., NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. *J. Org. Chem.* **1997**, *62*, (21), 7512-7515.

- (25) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D., Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures. *J. Org. Chem.* **1996**, *61*, (11), 3849-3862.
- (26) McLaughlin, M.; Palucki, M.; Davies, I. W., Efficient Access to Azaindoles and Indoles. *Org. Lett.* **2006**, *8*, (15), 3307-3310.
- (27) Liu, Z.-J.; Vors, J.-P.; Gesing, E. R. F.; Bolm, C., Ligand-Free Copper-Catalyzed Amination of Heteroaryl Halides with Alkyl- and Arylamines. *Adv. Synth. Catal.* **2010**, *352*, (18), 3158-3162.
- (28) Laha, J. K., Barolo, S. M.; Rossi, R. A.; Cuny, G. D., Synthesis of Carbolines by Photostimulated Cyclization of Anilinothalopyridines, *J. Org. Chem.* **2011**, *76*, (15), 6421–6425.